Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com..
BACKGROUND: Little is known about the effects of eradication of hepatitis C virus (HCV) on bone mineral density (BMD) and biomarkers of bone remodeling in human immunodeficiency virus (HIV)/HCV-coinfected patients.
METHODS: We prospectively assessed standardized BMD (sBMD) at the lumbar spine and femoral neck, World Health Organization BMD categories at both sites, and plasma concentrations of soluble receptor activator of NF-κβ ligand (sRANKL), and osteoprotegerin (OPG) at baseline (the date of initiation of anti-HCV therapy) and at 96 weeks.
RESULTS: A total of 238 patients were included. The median age was 49.5 years, 76.5% were males, 48.3% had cirrhosis, 98.3% were on antiretroviral therapy, median CD4+ cell count was 527 cells/μL, and 86.6% had HIV-1 RNA <50 copies/mL. The prevalence of osteoporosis at baseline at the lumbar spine (LS) and femoral neck (FN) was 17.6% and 7.2%, respectively. Anti-HCV therapy comprised pegylated interferon (peg-IFN) and ribavirin (RBV) plus 1 direct-acting antiviral in 53.4%, peg-IFN/RBV in 34.5%, and sofosbuvir/RBV in 12.2%. A total of 145 (60.9%) patients achieved sustained virologic response (SVR). No significant effect of SVR was observed on sBMD for the interaction between time and SVR either in the LS (P = .801) or the FN (P = .911). Likewise, no significant effect of SVR was observed in plasma levels of sRANKL (P = .205), OPG (P = .249), or sRANKL/OPG ratio (P = .123) for the interaction between time and SVR. No significant correlation was found between fibrosis by transient elastography, and LS and FN sBMD, at baseline and week 96.
CONCLUSIONS: SVR was not associated with significant changes in BMD nor biomarkers of bone remodeling in HIV/HCV-coinfected persons.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 7 vom: 05. Okt., Seite e2026-e2033 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carrero, Ana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
3WJQ0SDW1A |
|---|
| Anmerkungen: |
Date Completed 20.10.2021 Date Revised 20.10.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa1396 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315027061 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315027061 | ||
| 003 | DE-627 | ||
| 005 | 20231225154023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa1396 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315027061 | ||
| 035 | |a (NLM)32930720 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carrero, Ana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.10.2021 | ||
| 500 | |a Date Revised 20.10.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissionsoup.com. | ||
| 520 | |a BACKGROUND: Little is known about the effects of eradication of hepatitis C virus (HCV) on bone mineral density (BMD) and biomarkers of bone remodeling in human immunodeficiency virus (HIV)/HCV-coinfected patients | ||
| 520 | |a METHODS: We prospectively assessed standardized BMD (sBMD) at the lumbar spine and femoral neck, World Health Organization BMD categories at both sites, and plasma concentrations of soluble receptor activator of NF-κβ ligand (sRANKL), and osteoprotegerin (OPG) at baseline (the date of initiation of anti-HCV therapy) and at 96 weeks | ||
| 520 | |a RESULTS: A total of 238 patients were included. The median age was 49.5 years, 76.5% were males, 48.3% had cirrhosis, 98.3% were on antiretroviral therapy, median CD4+ cell count was 527 cells/μL, and 86.6% had HIV-1 RNA <50 copies/mL. The prevalence of osteoporosis at baseline at the lumbar spine (LS) and femoral neck (FN) was 17.6% and 7.2%, respectively. Anti-HCV therapy comprised pegylated interferon (peg-IFN) and ribavirin (RBV) plus 1 direct-acting antiviral in 53.4%, peg-IFN/RBV in 34.5%, and sofosbuvir/RBV in 12.2%. A total of 145 (60.9%) patients achieved sustained virologic response (SVR). No significant effect of SVR was observed on sBMD for the interaction between time and SVR either in the LS (P = .801) or the FN (P = .911). Likewise, no significant effect of SVR was observed in plasma levels of sRANKL (P = .205), OPG (P = .249), or sRANKL/OPG ratio (P = .123) for the interaction between time and SVR. No significant correlation was found between fibrosis by transient elastography, and LS and FN sBMD, at baseline and week 96 | ||
| 520 | |a CONCLUSIONS: SVR was not associated with significant changes in BMD nor biomarkers of bone remodeling in HIV/HCV-coinfected persons | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a bone | |
| 650 | 4 | |a hepatitis C | |
| 650 | 4 | |a osteoporosis | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 700 | 1 | |a Berenguer, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Hontañón, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Guardiola, Josep M |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a von Wichmann, Miguel A |e verfasserin |4 aut | |
| 700 | 1 | |a Téllez, María J |e verfasserin |4 aut | |
| 700 | 1 | |a Quereda, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Sanz, José |e verfasserin |4 aut | |
| 700 | 1 | |a Galindo, María J |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Quero, José |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Sousa, María A |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Latorre, Leire |e verfasserin |4 aut | |
| 700 | 1 | |a Bellón, José M |e verfasserin |4 aut | |
| 700 | 1 | |a Resino, Salvador |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban, Herminia |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez, Esteban |e verfasserin |4 aut | |
| 700 | 1 | |a González-García, Juan |e verfasserin |4 aut | |
| 700 | 0 | |a Grupo de Estudio del Sida (GESIDA) 3603B Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Carrero, A |e investigator |4 oth | |
| 700 | 1 | |a Miralles, P |e investigator |4 oth | |
| 700 | 1 | |a López, J C |e investigator |4 oth | |
| 700 | 1 | |a Parras, F |e investigator |4 oth | |
| 700 | 1 | |a Aldamiz-Echevarría, T |e investigator |4 oth | |
| 700 | 1 | |a Tejerina, F |e investigator |4 oth | |
| 700 | 1 | |a Díez, C |e investigator |4 oth | |
| 700 | 1 | |a Pérez-Latorre, L |e investigator |4 oth | |
| 700 | 1 | |a Fanciulli, C |e investigator |4 oth | |
| 700 | 1 | |a Gutiérrez, I |e investigator |4 oth | |
| 700 | 1 | |a Ramírez, M |e investigator |4 oth | |
| 700 | 1 | |a Carretero, S |e investigator |4 oth | |
| 700 | 1 | |a Catalán, P |e investigator |4 oth | |
| 700 | 1 | |a Pérez, M |e investigator |4 oth | |
| 700 | 1 | |a Bellón, J M |e investigator |4 oth | |
| 700 | 1 | |a Berenguer, J |e investigator |4 oth | |
| 700 | 1 | |a Hontañón, V |e investigator |4 oth | |
| 700 | 1 | |a Arribas, J R |e investigator |4 oth | |
| 700 | 1 | |a Montes, M L |e investigator |4 oth | |
| 700 | 1 | |a Bernardino, I |e investigator |4 oth | |
| 700 | 1 | |a Pascual, J F |e investigator |4 oth | |
| 700 | 1 | |a Zamora, F |e investigator |4 oth | |
| 700 | 1 | |a Peña, J M |e investigator |4 oth | |
| 700 | 1 | |a Arnalich, F |e investigator |4 oth | |
| 700 | 1 | |a Díaz, M |e investigator |4 oth | |
| 700 | 1 | |a González-García, J |e investigator |4 oth | |
| 700 | 1 | |a Domingo, P |e investigator |4 oth | |
| 700 | 1 | |a Guardiola, J M |e investigator |4 oth | |
| 700 | 1 | |a Torrella, A |e investigator |4 oth | |
| 700 | 1 | |a Planas, B |e investigator |4 oth | |
| 700 | 1 | |a Curran, A |e investigator |4 oth | |
| 700 | 1 | |a Navarro, J |e investigator |4 oth | |
| 700 | 1 | |a Casado, J L |e investigator |4 oth | |
| 700 | 1 | |a Dronda, F |e investigator |4 oth | |
| 700 | 1 | |a Moreno, A |e investigator |4 oth | |
| 700 | 1 | |a Pérez-Elías, M J |e investigator |4 oth | |
| 700 | 1 | |a Sanfrutos, M A |e investigator |4 oth | |
| 700 | 1 | |a Moreno, S |e investigator |4 oth | |
| 700 | 1 | |a Quereda, C |e investigator |4 oth | |
| 700 | 1 | |a Arranz, A |e investigator |4 oth | |
| 700 | 1 | |a Casas, E |e investigator |4 oth | |
| 700 | 1 | |a de Miguel, J |e investigator |4 oth | |
| 700 | 1 | |a Schroeder, S |e investigator |4 oth | |
| 700 | 1 | |a Sanz, J |e investigator |4 oth | |
| 700 | 1 | |a Sanz, J |e investigator |4 oth | |
| 700 | 1 | |a Santos, I |e investigator |4 oth | |
| 700 | 1 | |a Bustinduy, M J |e investigator |4 oth | |
| 700 | 1 | |a Iribarren, J A |e investigator |4 oth | |
| 700 | 1 | |a Rodríguez-Arrondo, F |e investigator |4 oth | |
| 700 | 1 | |a Von-Wichmann, M A |e investigator |4 oth | |
| 700 | 1 | |a Vergas, J |e investigator |4 oth | |
| 700 | 1 | |a Téllez, M J |e investigator |4 oth | |
| 700 | 1 | |a Vinuesa, D |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, L |e investigator |4 oth | |
| 700 | 1 | |a Hernández-Quero, J |e investigator |4 oth | |
| 700 | 1 | |a Ferrer, A |e investigator |4 oth | |
| 700 | 1 | |a Galindo, M J |e investigator |4 oth | |
| 700 | 1 | |a Ortiz, L |e investigator |4 oth | |
| 700 | 1 | |a Ortega, E |e investigator |4 oth | |
| 700 | 1 | |a Montero, M |e investigator |4 oth | |
| 700 | 1 | |a Blanes, M |e investigator |4 oth | |
| 700 | 1 | |a Cuellar, S |e investigator |4 oth | |
| 700 | 1 | |a Lacruz, J |e investigator |4 oth | |
| 700 | 1 | |a Salavert, M |e investigator |4 oth | |
| 700 | 1 | |a López-Aldeguer, J |e investigator |4 oth | |
| 700 | 1 | |a Pérez, G |e investigator |4 oth | |
| 700 | 1 | |a Gaspar, G |e investigator |4 oth | |
| 700 | 1 | |a Yllescas, M |e investigator |4 oth | |
| 700 | 1 | |a Crespo, P |e investigator |4 oth | |
| 700 | 1 | |a Aznar, E |e investigator |4 oth | |
| 700 | 1 | |a Esteban, H |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 7 vom: 05. Okt., Seite e2026-e2033 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:7 |g day:05 |g month:10 |g pages:e2026-e2033 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa1396 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 7 |b 05 |c 10 |h e2026-e2033 | ||